KESTRA MEDICAL TECHNOLOGIES, LTD. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Kestra Medical Technologies reported Q1 FY2027 revenue of $31.0M (up 60% YoY) with gross margin expanding to 56.5% from 45.7%. The company raised full-year FY2027 revenue guidance to $141M (48% growth), up from prior guidance of $137M. However, GAAP net loss widened to $44.1M from $25.8M YoY, and adjusted EBITDA loss deteriorated to $24.0M from $19.4M, driven by $6.3M debt extinguishment loss and accelerated R&D and commercial expansion spending. Cash and investments totaled $244.7M as of July 31, 2026.
Why this rating
Strong top-line growth (60% revenue, 11% guidance raise) and margin expansion are material for a $619M company, but widening losses and negative EBITDA offset gains. Adequate liquidity ($320M total) mitigates near-term risk.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.